A carregar...
Omalizumab in Children with Severe Allergic Asthma: The Italian Real-Life Experience
BACKGROUND: Anti-IgE treatment represents a major breakthrough in the therapeutic management of severe allergic asthma. To date, omalizumab is the only biological drug currently licensed as add-on therapy in children aged > 6 years with moderate-to-severe and severe allergic asthma uncontrolled a...
Na minha lista:
| Publicado no: | Curr Respir Med Rev |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Bentham Science Publishers
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5684803/ https://ncbi.nlm.nih.gov/pubmed/29213221 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2174/1573398X13666170426094536 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|